Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Surge Expected in Personal Flow Cytometry Market

By LabMedica International staff writers
Posted on 17 Feb 2011
The use of flow cytometers in biotech research laboratories should get a boost after the acquisition of a pioneer manufacturer of personal flow cytometers by one of the major international medical technology companies.

Flow cytometry is a method of sorting and measuring types of cells by fluorescent labeling of markers on the surface of the cells. More...
Accuri Cytometers, Inc. (Ann Arbor, MI, USA) was founded to address a compelling need: life scientists love the rapid cell-by-cell analysis capability of flow cytometers, but too few have a flow cytometer in their laboratory. The barriers for most researchers include cost of the instrument, complexity of the software, effort required for maintenance, and the large amount of bench space required for the instrument.

Accuri Cytometers developed the C6, a system so easy to operate and maintain that a dedicated operator is not required. New C6 users can be trained in less than 30 minutes. The C6 employs laboratory-grade water for sheath fluid so commercial sheath fluids are not needed. Maintenance is made simple with automatic rinse and decontamination upon instrument shutdown. No room renovations are required to install a C6, since it fits easily on the benchtop and uses standard electrical connections. The C6 is small enough to fit into every lab and can even be placed in a laminar flow hood

To secure a firm place at the head of the flow cytometry parade, Becton, Dickinson and Company (BD) (Franklin Lakes, NJ, USA) has acquired Accuri Cytometers. BD is a global medical technology company that is focused on improving drug delivery, enhancing the diagnosis of infectious diseases and cancers, and advancing drug discovery. BD develops, manufactures, and sells medical supplies, devices, laboratory instruments, antibodies, reagents, and diagnostic products. It serves healthcare institutions, life science researchers, clinical laboratories, and the pharmaceutical industry.

The acquisition is subject to regulatory approvals and is expected to close during the third quarter of fiscal year 2011.

"Making flow cytometry more accessible to a wider audience of scientists and clinicians is one aspect of our cell analysis growth strategy,” said William Rhodes, president of BD Biosciences. "With its small footprint, ease of use and affordable price, the Accuri flow cytometer enables the adoption of flow cytometry by a broad range of researchers whom BD does not currently serve.”

Related Links:
Accuri Cytometers, Inc.
Becton, Dickinson and Company (BD)




Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.